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Clinical Trial Enrollment

Results (continued)
• There was no significant difference in clinical trial enrollment
for black vs white patients (20.7% vs 16.7%, p=0.26).

• Clinical trials are integral to advancing cancer care
• Equitable accrual of research participants
ensures that clinical outcomes represent patients
from all backgrounds.

• There was significantly lower enrollment on clinical trial for
latinX patients than non-latinX patients (5.3% vs 18.4%,
p=0.034) (fig 1)

• Black and latinX patients are underrepresented in
clinical trials despite constituting most urban areas
where many clinical trials are available.

• Patients with uterine sarcomas were less likely (28.6%) and
patients with ovarian cancers (77.1%) were more likely to
have clinical trials discussed at their tumor board presentation
than those with other gynecologic cancers (65.4%).

• This study aims to determine whether presentation
at gynecologic oncology tumor board increases
clinical trial enrollment of black and latinX cancer
patients.

• Uninsured and incarcerated patients (51.4%) had significantly
lower rates of clinical trial discussions than patients with
Medicare (72%), Medicaid (67.3%), and private (69.7%)
insurance (p=0.04).

Methods

• There were significantly higher rates of clinical trial
discussion in patients with a family history of cancer, 72.8%,
vs 61.5% in patients without (p=0.027).

• A retrospective chart review of all cases
presented at multidisciplinary gynecologic oncology
tumor board from Jan 2019 – Jun 2022
was analyzed.

• Patients with advanced or recurrent cancer were more likely
to have a clinical trial discussed than patients with lower
stage disease (82.7% stage IV, 81.6% recurrent disease,
57.6% stage I, 55.9% stage II, 56.5% stage III, p<0.001).

• Demographic and cancer-specific variables as well
as tumor board discussions regarding clinical trials
were collected.

• English-speaking patients were more likely to enroll on trial
than Spanish-speaking patients (19% vs 3.8%, p=0.035).

• Continuous covariates were summarized within
groups by reporting means and compared
using Wilcoxon rank-sum tests.

• No significant difference in clinical trial discussion by
primary language, marital status, age, distance to treatment.

Clinical Trial Tumor Board Discussion

• Categorical covariates were summarized reporting
counts and compared using Fisher exact tests.

Conclusions
• Nationally 6.6% of black cancer patients enroll in clinical
trials. Here, we show that tumor board presentation led to
20.7% of black patients enrolling in clinical trials.

Results

• We found a lower enrollment rate of patients who identify
as latinX, this could be related to a language barrier as we
found significantly lower enrollment in patients whose
primary language was Spanish when compared to English
speakers.

• 349 cases reviewed. 43 cases excluded due to a
diagnosis of preinvasive disease, borderline tumor,
or non-gynecologic primary cancer.
• 226 patients had a clinical trial discussion at
their gynecologic oncology tumor
board presentation.
• Clinical trials were discussed at gynecologic
oncology tumor board for 71.7% of latinX patients
and 64.5% of black patients.

• Although latinX patients had a lower enrollment rate at
5.3%, it exceeded the national average of 1.9%.

Supporting literature: https://www-ncbi-nlm-nih-gov.ezproxy.lsuhsc.edu/pmc/articles/PMC8089053/

• In this population, we have demonstrated that presentation
at gynecologic oncology tumor board had a positive impact
on clinical trial enrollment for black and latinX patients.

